# A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer

> **NCT03516045** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 65 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** 18F-AlF-NOTA-neurotensin

## Key facts

- **NCT ID:** NCT03516045
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-23
- **Primary completion:** 2019-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516045, "A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03516045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*